Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

Liu, Shixian; Wang, Kaixuan; Chen, Hao; Wan, Ziming; Dou, Lei; Li, Shunping

doi:10.1186/s12962-025-00613-z

Cost Effectiveness and Resource Allocation

Table 1 Model parameter

From: Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

Parameters	Baseline	Range		Distribution	Source
Parameters	Baseline	Minimum	Maximum	Distribution	Source
Costs ($)
Sacituzumab govitecan per 180 mg	1192.05	953.64	1430.46	Gamma	[18]
Eribulin per 1 mg	101.17	80.94	121.41	Gamma	[18]
Capecitabine per 500 mg	0.69	0.56	0.83	Gamma	[18]
Gemcitabine per 200 mg	17.08	13.67	20.50	Gamma	[18]
Vinorelbine per 10 mg	19.05	15.24	22.86	Gamma	[18]
Best supportive care per cycle	359.00	287.20	430.80	Gamma	[20]
Laboratory tests per event	70.96	56.76	85.15	Gamma	local charges
CT of chest and abdomen per event	170.29	136.23	204.35	Gamma	local charges
Bone scan per event	113.53	90.82	136.23	Gamma	local charges
Routine follow-up per unit	38.39	30.71	46.07	Gamma	[21]
Cost of Neutropenia	701.00	560.80	841.20	Gamma	[22]
Cost of Anemia	531.70	425.36	638.04	Gamma	[23]
Cost of Leukopenia	446.05	356.84	535.26	Gamma	[19]
Cost of Diarrhea	44.30	35.44	53.16	Gamma	[21]
Cost of Fatigue	131.78	105.42	158.14	Gamma	[19]
Cost of Hypokalemia	3000.00	2400.00	3600.00	Gamma	[24]
Cost of Gamma-glutamyl transferase increased	1000.00	800.00	1200.00	Gamma	Assumption
Utility value
Utility of PFS	0.82	0.78	0.86	Beta	[26]
Utility of PD	0.55	0.44	0.66	Beta	[22]
Disutility of Neutropenia	0.15	0.12	0.18	Beta	[27]
Disutility of Anemia	0.07	0.06	0.09	Beta	[20]
Disutility of Leukopenia	0.13	0.10	0.16	Beta	[20]
Disutility of Diarrhea	0.10	0.08	0.12	Beta	[27]
Disutility of Fatigue	0.12	0.09	0.14	Beta	[27]
Disutility of Hypokalemia	0.04	0.03	0.05	Beta	[24]
Disutility of Gamma-glutamyl transferase increased	0.10	0.08	0.12	Beta	[20]
Adverse events (%)
Neutropenia of Chemotherapy	61.59	49.27	73.90	Beta	[8]
Anemia of Chemotherapy	6.10	4.88	7.32	Beta	[8]
Leukopenia of Chemotherapy	36.59	29.27	43.90	Beta	[8]
Gamma-glutamyl transferase increased of Chemotherapy	6.10	4.88	7.32	Beta	[8]
Neutropenia of SG	69.09	55.27	82.91	Beta	[8]
Anemia of SG	18.18	14.55	21.82	Beta	[8]
Leukopenia of SG	41.82	33.45	50.18	Beta	[8]
Diarrhea of SG	6.67	5.33	8.00	Beta	[8]
Fatigue of SG	7.27	5.82	8.73	Beta	[8]
Hypokalemia of SG	9.7	7.76	11.64	Beta	[8]
Other parameters
Discount rate (%)	5	0	8	Beta	[14]
Patient weight (kg)	57.37	45.90	68.84	Normal	[19]
Body surface area (m²)	1.72	1.38	2.06	Normal	[19]

Note: CT, Computed tomography; PFS, progression-free survival; PD, progressive disease; SG, sacituzumab govitecan

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com